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The different names used for trientine and triethylenetetramine 
Some chemistry of triethylenetetramine (trientine) 
In chemistry, a salt is formed when an acid is mixed with an equivalent amount of a base, usually in 
aqueous solution. For example, by mixing dilute hydrochloric acid with the correct proportion of 
aqueous sodium hydroxide (a base), sodium chloride (common salt) is formed and may be isolated by 
evaporating off the water.  
Triethylenetetramine is also a base which on mixing with hydrochloric acid (HCl) in water can 
produce two salts depending on the amount of HCl added. The first salt produced is 
triethylenetetramine dihydrochloride. By adding further amounts of HCl the dihydrochloride is 
converted into a second salt, triethylenetetramine tetrahydrochloride. Both salts may be isolated as 
crystalline solids by evaporating the two respective aqueous solutions under reduced pressure [di = 
two; tetra = four]. 
A better understanding of these two salts comes from looking at the chemical structure of 
triethylenetetramine: H2NCH2CH2NHCH2CH2NHCH2CH2NH2. This compound contains four 
nitrogen atoms (N) (shown in red). The rest of the molecule consists of six carbon atoms and eighteen 
hydrogen atoms (C and H). In the dihydrochloride the two terminal nitrogen atoms interact with HCl; 
in the tetrahydrochloride, all four nitrogen atoms interact with HCl. A unique property of 
triethylenetetramine is that the four nitrogen atoms can wrap around copper (as cupric ions) to form a 
chelate. In the jargon of chemistry, triethylenetetramine complexes with cupric ions to form a chelate 
(also called a coordination compound). It is this property that allows triethylenetetramine to be used 
so effectively for treating Wilson’s disease. 
Triethylenetetramine base is a liquid. It is more convenient to administer a (solid) salt of 
triethylenetetramine to patients. Since its introduction by Dr John Walshe in 1969, 
triethylenetetramine dihydrochloride has been used to treat Wilson’s disease. Recently (2018) a 
French company GMP-Orphan SAS has initiated clinical trials of triethylenetetramine 
tetrahydrochloride for the treatment of Wilson’s disease. Therapeutically, both the dihydrochloride 
and the tetrahydrochloride salts revert to the free base, triethylenetetramine, in the body. With copper, 
the resulting triethylenetetramine–copper chelate is then excreted in the patient’s urine thus reducing 
the overall body burden of copper in patients with Wilson’s disease. 
The different names used for triethylenetetramine dihydrochloride and 
triethylenetetramine 
Rather than the common chemical name, triethylenetetramine, the generic name trientine has been 
adopted when triethylenetetramine is used as a drug. Trientine’s copper chelating properties have 
also been investigated for the treatment of diseases unrelated to Wilson’s disease. As a result, 
triethylenetetramine dihydrochloride has acquired a number of approved, colloquial, trade and 
code names. There are two (generic) Approved Names for this drug: trientine dihydrochloride, 
which is the British Approved Name (BAN) and the World Health Organization (WHO) International 
Nonproprietary Name (INN) and trientine hydrochloride, which is the United States Adopted Name 
(USAN). These two names refer to the same product – trientine dihydrochloride. 
Pharmaceutical manufacturers/traders who provide trientine dihydrochloride for patients each use a 
different trade name for the drug. Trade names used by four companies which supply trientine 
dihydrochloride are shown in the Table below. 
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Table: Some trade names used for trientine dihydrochloride 
Trade 
name 
Company/country  Trientine dihydrochloride 
content/capsule (mg) 
Trientine free 
base/capsule (mg) 
Principal 
region(s) 
supplied 
Syprine† Bausch Health 
Companies/USA 
250 167 USA 
Cufence Univar Solutions B.V./The 
Netherlands 
300 200 Europe‡ 
Metalite Tsumura/Japan 250 167 Japan 
Cuchel MSN Laboratories/India 250 167 India 
 
† Syprine is available from other USA companies listed on the website https://www.drugs.com/availability/generic-syprine.html 
(accessed 9th September 2019).  
‡ At present (2019) Univar markets trientine dihydrochloride in the UK under its generic name. 
Other brand and code names for trientine which appear in the literature and on the web include Cuprid (Merck); Laszarin 
(Protemix); MK-681; PX 811019 (Protemix); KD034 (Kadmon). Merck is a USA pharmaceutical company, which relinquished its 
interests in trientine in 2004, Protemix a former New Zealand biotech company, and Kadmon a USA company. Trientine is 
wrongly spelt ‘trientene’ in several scientific papers, which may be found from a Google Scholar search.  
As mentioned above, trientine dihydrochloride and trientine tetrahydrochloride are prepared from 
triethylenetetramine. Triethylenetetramine itself has multiple applications, and also has acquired many 
different chemical names and code names, which are often used in the chemical literature: 
triethylenetetramine; N,N'-bis(2-aminoethyl)-1,2-ethanediamine; 1,8-diamino-3,6-diazaoctane; 3,6-
diaza-1,8-octanediamine; 1,4,7,10-tetraazadecane; trien; TETA. All these names refer to the same 
substance, triethylenetetramine (the free base). 
Cufence 200 mg capsules 
In May 2019, the European Medicines Agency’s (EMA) Committee for Medicinal Products for 
Human Use (CHMP) granted marketing authorisation for Univar’s trientine dihydrochloride. This 
decision will facilitate the availability of trientine dihydrochloride in the European Union. As part of 
its application for EMA recognition, Univar has adopted the trade name Cufence for trientine 
dihydrochloride. Cufence capsules will be labelled ‘Cufence capsules 200 mg’.  The ‘200 mg’ refers 
to the amount of trientine (triethylenetetramine) base in each capsule. In the UK, these same capsules 
are labelled ‘trientine dihydrochloride capsules 300 mg’. The ‘300 mg’ refers to the amount of 
trientine dihydrochloride in each capsule. The explanation of these two different amounts is as 
follows: 
The molecular formula of trientine base (triethylenetetramine) is C6H18N4 which has a molar mass 146.2 
grams/mole [the sum of the atomic masses of 6 x carbon atoms, 18 x hydrogen atoms and 4 x nitrogen atoms]. 
The molecular formula of trientine dihydrochloride is C6H18N4.2HCl which has a molar mass 219.2 grams/mole. 
One mole (146.2 g) of trientine base is equivalent to one mole (219.2 g) of trientine dihydrochloride. Hence 
200 mg trientine base = (219.2 ÷ 146.2) x 200 = 300 mg trientine dihydrochloride. 
Cuprior 150 mg tablets 
The trade name for trientine tetrahydrochloride chosen by GMP-Orphan SAS is Cuprior, which 
will be marketed as film-coated tablets each containing the equivalent of 150 mg trientine free base. 
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